Tocagen (TOCA) Presents Updated Durable CR Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High ... - StreetInsider.com

Tocagen (TOCA) Presents Updated Durable CR Data from Phase 1 Trial of Toca 511 & Toca FC in Recurrent High ... StreetInsider.com Tocagen Inc. (Nasdaq: TOCA), a clinical-stage, cancer-selective gene therapy company, today reported updated data demonstrating long-term durable responses, and the conversion of initial partial responses (PRs) into complete responses (CRs), from a ... and more »

from Health - Google News http://ift.tt/2gMUYt9